$MEIP
MEI Pharma, Inc.

2021 Q3 Form 10-Q Financial Statement

#000095017021004063 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q3
Revenue $13.39M $19.38M $3.834M
YoY Change 249.17% -24.02% 231.37%
Cost Of Revenue $0.00 $509.0K
YoY Change -100.0% -26.02%
Gross Profit $13.39M $19.38M $3.325M
YoY Change 302.62% -22.55% 608.96%
Gross Profit Margin 100.0% 100.0% 86.72%
Selling, General & Admin $7.909M $6.634M $5.920M
YoY Change 33.6% 46.45% 43.34%
% of Gross Profit 59.08% 34.24% 178.05%
Research & Development $19.95M $16.29M $13.00M
YoY Change 53.53% 107.3% 45.01%
% of Gross Profit 149.05% 84.09% 390.86%
Depreciation & Amortization $77.00K $65.00K $69.00K
YoY Change 11.59% 225.0% 122.58%
% of Gross Profit 0.58% 0.34% 2.08%
Operating Expenses $19.95M $22.93M $13.00M
YoY Change 53.53% 85.05% 45.01%
Operating Profit -$14.48M -$3.551M -$15.59M
YoY Change -7.13% -128.12% 23.47%
Interest Expense $2.595M $7.100M $13.50M
YoY Change -80.78% -122.82% 40.04%
% of Operating Profit
Other Income/Expense, Net $0.00 $4.000K -$10.00K
YoY Change -100.0% 0.0%
Pretax Income -$17.51M $3.553M -$2.090M
YoY Change 737.8% -119.23% -30.1%
Income Tax $8.000K
% Of Pretax Income 0.23%
Net Earnings -$17.51M $3.545M $712.0K
YoY Change -2559.27% -119.19% -123.78%
Net Earnings / Revenue -130.8% 18.29% 18.57%
Basic Earnings Per Share -$0.11 -$0.02
Diluted Earnings Per Share -$0.13 $31.49K -$0.13
COMMON SHARES
Basic Shares Outstanding 112.7M 112.6M 112.4M
Diluted Shares Outstanding 113.9M 115.0M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $145.5M $153.4M $176.1M
YoY Change -17.37% -15.98% 167.22%
Cash & Equivalents $15.62M $8.543M $10.96M
Short-Term Investments $129.9M $144.9M $165.2M
Other Short-Term Assets $3.739M $3.809M $2.000M
YoY Change 86.95% -23.82% 17.65%
Inventory
Prepaid Expenses
Receivables $10.00M $5.400M
Other Receivables $0.00 $0.00 $20.40M
Total Short-Term Assets $167.4M $164.8M $203.9M
YoY Change -17.93% -21.01% 199.67%
LONG-TERM ASSETS
Property, Plant & Equipment $1.438M $1.507M $1.659M
YoY Change -13.32% 39.02% 168.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $8.989M $9.281M $10.08M
YoY Change -10.81% 756.18% 1055.85%
TOTAL ASSETS
Total Short-Term Assets $167.4M $164.8M $203.9M
Total Long-Term Assets $8.989M $9.281M $10.08M
Total Assets $176.4M $174.1M $214.0M
YoY Change -17.6% -16.99% 210.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.472M $6.355M $6.375M
YoY Change 32.89% 160.77% 105.78%
Accrued Expenses $6.099M $8.402M $5.537M
YoY Change 10.15% 37.96% 68.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.37M $20.21M $31.49M
YoY Change -3.56% -13.27% 212.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $121.2M $104.4M $100.2M
YoY Change 20.97% -3.49% 763.79%
Total Long-Term Liabilities $121.2M $104.4M $100.2M
YoY Change 20.97% -3.49% 763.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.37M $20.21M $31.49M
Total Long-Term Liabilities $121.2M $104.4M $100.2M
Total Liabilities $144.5M $124.6M $131.7M
YoY Change 9.75% -5.23% 508.42%
SHAREHOLDERS EQUITY
Retained Earnings -$339.7M -$319.7M -$279.3M
YoY Change 21.61% 15.32% 19.26%
Common Stock $371.5M $369.2M $361.7M
YoY Change 2.73% 3.86% 28.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $34.30M $49.47M $83.98M
YoY Change
Total Liabilities & Shareholders Equity $176.4M $174.1M $214.0M
YoY Change -17.6% -16.99% 210.5%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q3
OPERATING ACTIVITIES
Net Income -$17.51M $3.545M $712.0K
YoY Change -2559.27% -119.19% -123.78%
Depreciation, Depletion And Amortization $77.00K $65.00K $69.00K
YoY Change 11.59% 225.0% 122.58%
Cash From Operating Activities -$7.721M -$11.25M -$9.111M
YoY Change -15.26% -116.28% -35.28%
INVESTING ACTIVITIES
Capital Expenditures $8.000K -$8.000K $644.0K
YoY Change -98.76% -92.0%
Acquisitions
YoY Change
Other Investing Activities $15.00M $9.996M $5.120M
YoY Change 192.99% -111.77% 3.02%
Cash From Investing Activities $14.99M $9.988M $4.476M
YoY Change 234.96% -111.75% -9.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $3.136M
YoY Change -100.0% 1872.33%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -194.0K 68.00K 3.260M
YoY Change -105.95% -99.67% -40.78%
NET CHANGE
Cash From Operating Activities -7.721M -11.25M -9.111M
Cash From Investing Activities 14.99M 9.988M 4.476M
Cash From Financing Activities -194.0K 68.00K 3.260M
Net Change In Cash 7.078M -1.198M -1.375M
YoY Change -614.76% -124.45% -61.87%
FREE CASH FLOW
Cash From Operating Activities -$7.721M -$11.25M -$9.111M
Capital Expenditures $8.000K -$8.000K $644.0K
Free Cash Flow -$7.729M -$11.25M -$9.755M
YoY Change -20.77% -116.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
CY2021Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2021Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
CY2021Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
CY2021Q3 meip Non Cash Lease Expense
NonCashLeaseExpense
CY2021Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2028-03-31
CY2021Q3 us-gaap Interest Expense Other
InterestExpenseOther
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
CY2021Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001262104
CY2020Q3 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
CY2021Q2 meip Accounts Receivable Net Beginning Balance
AccountsReceivableNetBeginningBalance
CY2021Q3 dei Document Type
DocumentType
10-Q
CY2021Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q3 dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
CY2021Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q3 dei Entity File Number
EntityFileNumber
000-50484
CY2021Q3 dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
CY2021Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
51-0407811
CY2021Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
11455 El Camino Real
CY2021Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2021Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2021Q3 dei City Area Code
CityAreaCode
858
CY2021Q3 dei Local Phone Number
LocalPhoneNumber
369-7100
CY2021Q3 dei Security12b Title
Security12bTitle
Common Stock, $0.00000002 par value
CY2021Q3 dei Trading Symbol
TradingSymbol
MEIP
CY2021Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q3 dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
112721212
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15621000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8543000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
129882000
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
144883000
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
145503000
CY2021Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
153426000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10000000
CY2021Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8120000
CY2021Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7582000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3739000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3809000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
167362000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
164817000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7551000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7774000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1438000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1507000
CY2021Q3 us-gaap Assets
Assets
176351000
CY2021Q2 us-gaap Assets
Assets
174098000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8472000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6355000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6099000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8402000
CY2021Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14837000
CY2021Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14609000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
957000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
928000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
30365000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
30294000
CY2021Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
87276000
CY2021Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
72717000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7115000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7370000
CY2021Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
19768000
CY2021Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
22355000
CY2021Q3 us-gaap Liabilities
Liabilities
144524000
CY2021Q2 us-gaap Liabilities
Liabilities
132736000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
112678000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
112678000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
112615000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
112615000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
371516000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
369171000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-339689000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-327809000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
31827000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
41362000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
176351000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
174098000
CY2021Q3 us-gaap Revenues
Revenues
13387000
CY2020Q3 us-gaap Revenues
Revenues
3834000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
509000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19953000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12996000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7909000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5915000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
27862000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
19420000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14475000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15586000
CY2021Q3 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
2587000
CY2020Q3 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
13224000
CY2021Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
8000
CY2020Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
275000
CY2020Q3 us-gaap Interest Expense Other
InterestExpenseOther
5000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11880000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2092000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11880000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2092000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14467000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15316000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2021Q3 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Reclassifications</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain reclassifications have been made to the prior year financial statements to conform to the current year financial statement presentation of contract assets. These changes did not impact previously reported net loss, loss per share, stockholders’ equity, total assets or cash flows.</span></p>
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112677000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112435000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113917000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114957000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
41362000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11880000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-194000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2539000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
31827000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
78218000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2092000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3136000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
124000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2942000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
82328000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-11880000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-2092000
CY2021Q3 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
2587000
CY2020Q3 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
13224000
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2539000
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2942000
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
77000
CY2020Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
69000
CY2020Q3 meip Non Cash Lease Expense
NonCashLeaseExpense
269000
CY2021Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10000000
CY2021Q3 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
538000
CY2020Q3 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
2061000
CY2021Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-70000
CY2020Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-280000
CY2021Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2117000
CY2020Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
3938000
CY2021Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2303000
CY2020Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-553000
CY2021Q3 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
14787000
CY2020Q3 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1336000
CY2021Q3 meip Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-3000
CY2020Q3 meip Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-15000
CY2021Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7721000
CY2020Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9111000
CY2021Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000
CY2020Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
644000
CY2021Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
59992000
CY2020Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
54989000
CY2021Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
74993000
CY2020Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
60109000
CY2021Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14993000
CY2020Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4476000
CY2021Q3 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
194000
CY2020Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
124000
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3136000
CY2021Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-194000
CY2020Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3260000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7078000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1375000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8543000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12331000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15621000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10956000
CY2020Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-8000
CY2021Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2020Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8689000
CY2021Q3 meip Number Of Clinical Stage Candidates
NumberOfClinicalStageCandidates
3
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-339700000
CY2021Q3 meip Cash And Cash Equivalentsshort Term Investments And Common Stock Proceeds Receivable
CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable
145500000
CY2020Q3 meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
3600000
CY2020Q2 meip Accounts Receivable Net Beginning Balance
AccountsReceivableNetBeginningBalance
83000
CY2021Q3 meip Receivables Amounts Billed
ReceivablesAmountsBilled
27638000
CY2021Q3 us-gaap Revenues
Revenues
13387000
CY2020Q3 us-gaap Revenues
Revenues
3834000
CY2021Q3 meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
13400000
CY2021Q3 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates.</span></p>
CY2021Q3 us-gaap Revenues
Revenues
13387000
CY2020Q3 us-gaap Revenues
Revenues
3834000
CY2020Q3 meip Receivables Amounts Billed
ReceivablesAmountsBilled
2727000
CY2021Q3 meip Receivables Payments Received
ReceivablesPaymentsReceived
-17638000
CY2020Q3 meip Receivables Payments Received
ReceivablesPaymentsReceived
-2693000
CY2021Q3 meip Accounts Receivable Net Ending Balance
AccountsReceivableNetEndingBalance
10000000
CY2020Q3 meip Accounts Receivable Net Ending Balance
AccountsReceivableNetEndingBalance
117000
CY2021Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7582000
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2858000
CY2021Q3 meip Contract Assets Billable Amounts
ContractAssetsBillableAmounts
28176000
CY2020Q3 meip Contract Assets Billable Amounts
ContractAssetsBillableAmounts
5114000
CY2021Q3 meip Contract Assets Amounts Billed
ContractAssetsAmountsBilled
-27638000
CY2020Q3 meip Contract Assets Amounts Billed
ContractAssetsAmountsBilled
-2727000
CY2021Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8120000
CY2020Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
5245000
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
22781000
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
17955000
CY2021Q3 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
14787000
CY2020Q3 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1336000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
37568000
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
19291000
CY2021Q3 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
102100000
CY2021Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q3 meip Potential Milestone Payments Payable
PotentialMilestonePaymentsPayable
20000000.0
CY2021Q3 meip Potential Milestone Payments Receivable
PotentialMilestonePaymentsReceivable
10000000.0
CY2021Q3 meip Expected Milestone Payment Receivable
ExpectedMilestonePaymentReceivable
10000000.0
CY2021Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2020Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11880000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2092000
CY2021Q3 meip Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-2587000
CY2020Q3 meip Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-13224000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14467000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15316000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112677000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112435000
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1240000
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2522000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113917000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114957000
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21141000
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15557000
CY2020Q3 meip Initial Recognition Of Operating Lease Right Of Use Asset
InitialRecognitionOfOperatingLeaseRightOfUseAsset
8700000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8700000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
377000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
377000
CY2021Q3 meip Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
380000
CY2020Q3 meip Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
123000
CY2021Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2020Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8689000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1139000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1565000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1612000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1168000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1710000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1761000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
1360000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10315000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2243000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8072000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
957000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7115000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8072000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y6M
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0750
CY2021Q3 meip Unsold Securities Shares And Warrants Under Agreement
UnsoldSecuritiesSharesAndWarrantsUnderAgreement
107500000
CY2021Q3 meip Aggregate Value Of Securities Available Under Agreement
AggregateValueOfSecuritiesAvailableUnderAgreement
175700000
CY2021Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
19800000
CY2021Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
22400000
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2539000
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2942000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16668542
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.01
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5051400
CY2021Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.93
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1078419
CY2021Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.10
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20641523
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.98
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4131984
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
9748144
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.86
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3610815
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.004
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.678
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.806
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.78
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.35
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
13000000.0
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D

Files In Submission

Name View Source Status
0000950170-21-004063-index-headers.html Edgar Link pending
0000950170-21-004063-index.html Edgar Link pending
0000950170-21-004063.txt Edgar Link pending
0000950170-21-004063-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img102216177_0.jpg Edgar Link pending
img102216177_1.jpg Edgar Link pending
meip-20210930.htm Edgar Link pending
meip-20210930.xsd Edgar Link pending
meip-20210930_cal.xml Edgar Link unprocessable
meip-20210930_def.xml Edgar Link unprocessable
meip-20210930_htm.xml Edgar Link completed
meip-20210930_lab.xml Edgar Link unprocessable
meip-20210930_pre.xml Edgar Link unprocessable
meip-ex31_1.htm Edgar Link pending
meip-ex31_2.htm Edgar Link pending
meip-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending